TREAT TO TARGET STRATEGY PLUS CERTOLIZUMAB IN COMPARISON TO CONTINUED, FIXED CSDMARD PLUS CORTICOSTEROIDS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS (REMISSION BY INTRA-ARTICULAR INJECTION PLUS CERTOLIZUMAB, THE RICE STUDY): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL

被引：0
|
作者：
Mueller, R. [1 ]
Spaeth, M. [2 ]
von Restorff, C.
Ackermann, C.
von Kempis, J. [1 ]
机构：
[1] Kantonsspital St Gallen, Dept Rheumatol, St Gallen, Switzerland
[2] Spital Linth, Div Rheumatol, Uznach, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0138
引用
收藏
页码：613 / 613
页数：1
相关论文
共 7 条
  • [1] The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
    Mueller, Ruediger
    Spaeth, Michael
    von Restorff, Cord
    Ackermann, Christoph
    von Kempis, Johannes
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
    Mueller, Ruediger B.
    Spaeth, Michael
    von Restorff, Cord
    Ackermann, Christoph
    Schulze-Koops, Hendrik
    von Kempis, Johannes
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03):
  • [3] Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Tanaka, Yoshiya
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Shoji, Toshiharu
    Sakamaki, Yoshiharu
    van der Heijde, Desiree
    Miyasaka, Nobuyuki
    Koike, Takao
    MODERN RHEUMATOLOGY, 2014, 24 (05) : 715 - 724
  • [4] Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial
    Masic, Dzenan
    Stengaard-Pedersen, Kristian
    Logstrup, Brian Bridal
    Horslev-Petersen, Kim
    Hetland, Merete Lund
    Junker, Peter
    ostergaard, Mikkel
    Ammitzboll, Christian
    Moller, Soren
    Christensen, Robin
    Ellingsen, Torkell
    RHEUMATOLOGY INTERNATIONAL, 2021, 41 (03) : 543 - 549
  • [5] Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial
    Dženan Mašić
    Kristian Stengaard-Pedersen
    Brian Bridal Løgstrup
    Kim Hørslev-Petersen
    Merete Lund Hetland
    Peter Junker
    Mikkel Østergaard
    Christian Ammitzbøll
    Sören Möller
    Robin Christensen
    Torkell Ellingsen
    Rheumatology International, 2021, 41 : 543 - 549
  • [6] Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
    Horslev-Petersen, Kim
    Hetland, Merete Lund
    Junker, Peter
    Podenphant, Jan
    Ellingsen, Torkell
    Ahlquist, Palle
    Lindegaard, Hanne
    Linauskas, Asta
    Schlemmer, Annette
    Dam, Mette Yde
    Hansen, Ib
    Horn, Hans Christian
    Ammitzboll, Christian Gytz
    Jorgensen, Anette
    Krintel, Sophine B.
    Raun, Johnny
    Johansen, Julia S.
    Ostergaard, Mikkel
    Stengaard-Pedersen, Kristian
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (04) : 654 - 661
  • [7] Adalimumab Added to a Treat-to-Target Strategy with Methotrexate and Intra-Articular Triamcinolone in Early Rheumatoid Arthritis Increased Remission Rates, Function and Quality of Life. The OPERA Study: An Investigator-Initiated, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Trial
    Lunzer, R.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2013, 20 (03): : 116 - 117
1